Avalyn Pharma nets $35.5m Series B

Seattle-based Avalyn Pharma Inc, a biopharmaceutical company focused on treating life threatening pulmonary diseases, has secured $35.5 million in Series B financing.

ByIris Dorbian

27 April 2020•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Deals Healthcare Briefs

Avalyn Pharma nets $35.5m Series B

F-Prime Capital

Novo Holdings A/S

RiverVest Venture Partners

Related articles